CXCR4 and non-Hodgkin lymphoma: A few classes of CXCR4 antagonists have undergone clinical trials, including peptide inhibitors, small molecule inhibitors, and monoclonal antibodies such as Plerixafor, which is approved by the Food and Drug Administration (FDA) for the treatment of non-Hodgkin’s lymphoma and multiple myeloma [23].